EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy

Esther Reijnders iD, Patrick M Bossuyt iD, J Wouter Jukema iD, L Renee Ruhaak iD, Fred P H T M Romijn iD, Michael Szarek iD, Stella Trompet iD, Deepak L Bhatt iD, Vera A Bittner iD, Rafael Diaz, Sergio Fazio iD, Irena Stevanovic iD und 6 weitere

Arteriosclerosis, Thrombosis, and Vascular Biology · 2025

DOI: 10.1161/atvbaha.124.322336 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2025. Verfasst von Esther Reijnders und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Chemistry and Laboratory Medicine (E.R., L.R.R., F. P.H.T.M.R., C.M.C.), Leiden University Medical Center, the Netherlands. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized, Anticholesteremic Agents, Apolipoproteins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Residual cardiovascular risk remains, despite achieving low-density lipoprotein cholesterol targets with high-intensity statins. Traditional risk scores are suboptimal. This study evaluated the prognostic utility of a 9-plex apolipoprotein panel in recent patients with acute coronary syndrome on statins and its role in predicting treatment benefit by alirocumab, a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor, enabling precision medicine. METHODS: Baseline serum samples from 11 843 participants in the ODYSSEY OUTCOMES trial ( https://www.clinicaltrials.gov ; Unique identifier: NCT01663402) were analyzed using mass spectrometry to measure Apo(a), ApoA-I, ApoA-II, ApoA-IV, ApoB, ApoC-I, ApoC-II, ApoC-III, and ApoE. Using logistic regression, probabilities of major adverse cardiovascular events (MACE) and all-cause death over a median follow-up of 2.9 years were estimated based on baseline apolipoproteins and lipid concentrations. Clinical performance was assessed by comparing the area under the curve (AUC) of 3 models: the apolipoprotein panel, the lipid panel (total cholesterol, high-density lipoprotein cholesterol, and triglycerides), and a combination. In addition, prediction models estimating the treatment benefit of alirocumab by the apolipoprotein panel were developed. RESULTS: The prognostic performance of the apolipoprotein panel for MACE showed an AUC (95% CI) of 0.648 (0.626–0.670), compared with 0.579 (0.557–0.602) for the lipid panel. For all-cause death, the apolipoprotein panel had an AUC of 0.699 (0.664–0.733), while the lipid panel had an AUC of 0.599 (0.564–0.635). Adding the apolipoprotein panel significantly improved the performance of the conventional lipid panel ( P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromeAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsApolipoproteinsCardiovascular DiseasesDyslipidemiasPCSK9 InhibitorsSerine Proteinase InhibitorsAgedFemaleHumansMaleMiddle AgedBiomarkersHydroxymethylglutaryl-CoA Reductase InhibitorsPrecision MedicinePredictive Value of TestsProprotein Convertase 9Risk AssessmentTime FactorsTreatment Outcome

Stichwörter der Autor:innen

acute coronary syndromealirocumabapolipoproteinsprognosisrisk

Substanzen

alirocumabAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsApolipoproteinsBiomarkersHydroxymethylglutaryl-CoA Reductase InhibitorsPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9Serine Proteinase Inhibitors

Autor:innen und Institutionen

  • Department of Clinical Chemistry and Laboratory Medicine (E.R., L.R.R., F. P.H.T.M.R., C.M.C.), Leiden University Medical Center, the Netherlands.
  • Department of Epidemiology and Data Science, Amsterdam UMC, The Netherlands (P.M.B.).
  • Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands.
  • Department of Cardiology, Netherlands Heart Institute, Utrecht (J.W.J.).
  • Division of Cardiology, University of Colorado School of Medicine, Aurora (M.S., G.G.S.).
  • CPC Clinical Research, Aurora, CO (M.S.).

ORCID-Profile: Esther Reijnders, Patrick M Bossuyt, J Wouter Jukema, L Renee Ruhaak, Fred P H T M Romijn, Michael Szarek, Stella Trompet, Deepak L Bhatt, Vera A Bittner, Sergio Fazio, Irena Stevanovic, Shaun G Goodman, Robert A Harrington, Harvey D White, Philippe Gabriel Steg, Gregory G Schwartz, Christa M Cobbaert

Zitieren

APA

Reijnders, E., Bossuyt, P. M., Jukema, J. W., Ruhaak, L. R., Romijn, F. P. H. T. M., Szarek, M., Trompet, S., Bhatt, D. L., Bittner, V. A., Diaz, R., Fazio, S., Stevanovic, I., Goodman, S. G., Harrington, R. A., White, H. D., Steg, P. G., Schwartz, G. G., & Cobbaert, C. M. (2025). Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.124.322336

Vancouver

Reijnders E, Bossuyt PM, Jukema JW, Ruhaak LR, Romijn FPHTM, Szarek M, et al. Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy. Arteriosclerosis, Thrombosis, and Vascular Biology. 2025. doi:10.1161/atvbaha.124.322336

BibTeX
@article{Reijnders2025,
  author = {Reijnders, Esther and Bossuyt, Patrick M and Jukema, J Wouter and Ruhaak, L Renee and Romijn, Fred P H T M and Szarek, Michael and Trompet, Stella and Bhatt, Deepak L and Bittner, Vera A and Diaz, Rafael and Fazio, Sergio and Stevanovic, Irena and Goodman, Shaun G and Harrington, Robert A and White, Harvey D and Steg, Philippe Gabriel and Schwartz, Gregory G and Cobbaert, Christa M},
  title = {Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy},
  journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
  year = {2025},
  doi = {10.1161/atvbaha.124.322336}
}
Kostenlos starten →